TESICO (Therapeutics for Severely Ill Inpatients with COVID-19) is a master protocol to evaluate the safety and efficacy of investigational agents aimed at improving outcomes for patients with acute respiratory failure related to COVID-19.

Armata Pharmaceuticals, Inc. (Armata) has begun a study of an investigational drug (also known as the "study drug") called AP-PA02 as a possible treatment for individuals with cystic fibrosis (CF) and chronic pulmonary Pseudomonas aeruginosa (Pa) infection. The main purposes of this study are to learn about how safe and how well tolerated the study drug is compared to the placebo. This study has two parts, Part 1 and Part 2. You may only participate in Part 1 or Part 2, not both. If you participate in Part 1 of the study, the screening period is up to 21 days, and the on-study period is 29 days, for a total of up to 50 days, and you will need to come to the study center 8 times over this study period. If you are in Part 2 of the study, the screening period is up to 21 days, and the on-study period is 31 days, for a total of up to 52 days, and you will need to come to the study center 10 times over this study period. This study will take place in approximately 12 centers in the United States with about 48 people with CF and chronic Pa participating.

The purpose of the study is to help doctors learn more about investigational dupilumab (the study drug) and to find out how safe it is and how well it works for patients with asthma. The study will investigate whether the study drug can help to improve the health of your lungs, reduce the inflammation in your airways and also improve your quality of life. If you join the study, your participation will last a minimum of 29 weeks and up to 41 weeks and is planned to include approximately 153 participants. The study will be conducted worldwide. If the study is suited for you, you will be randomized by chance (like drawing straws) to receive either the study drug (300 mg dupilumab) or placebo.

This is a randomized, double-blind, placebo-controlled, active comparator study in eligible subjects with a new diagnosis of MAC lung infection. The purpose of this study is to validate a patient-reported outcomes questionnaire in newly diagnosed subjects given amikacin liposome inhalation suspension (ALIS) as part of a study treatment regimen for NTM caused by MAC. This study will also evaluate the safety and efficacy of the study treatments with ALIS inhalation therapy, azithromycin (AZI) and ethambutol (ETH). Around 100 subjects 18 years and above of age with newly diagnosed NTM caused by MAC are expected to participate in this study. The study will last around 9.5 months from the Screening visit to the end of the study.

The purpose of this study is to evaluate the effect and safety of amikacin liposome inhalation suspension (ALIS) study treatment on patient-reported symptoms in subjects newly diagnosed with NTM lung infection caused by MAC who have not started standard treatment. Around 250 subjects 18 years and older with newly diagnosed NTM lung infection caused by MAC who have not started standard treatment are expected to participate in this study. The study will last around 17.5 months from the Screening visit to the end of the study.

This is a randomized, double-blind, placebo-controlled study designed to evaluate treatment with brexanolone in participants with acute respiratory distress syndrome due to COVID-19.Participants will receive continued standard of care in addition to a continuous IV infusion of brexanolone or placebo for 60 hours while hospitalized. Study participation will last approximately 28 days.

This study is testing an experimental drug called "LY3819253" that will provide antibodies that is thought to fight the COVID-19 virus.The subject will receive the study drug (either the experimental study drug or the placebo) only once, on the day he/she joins the study (study "Day 0"). The subject will get it by an intravenous (IV) drip through a tube attached to a needle in the arm. This is called an infusion. As part of the study the subject will also get a study drug called remdesivir once a day intravenously for up to 10 days while in the hospital, as care for COVID-19, unless the study doctor thinks remdesivir would not be safe to be taken. The study will last for 90 days.

This is a prospective cohort study of subjects with portal hypertension to examine whether increased sphingosine 1 phosphate : ceramide ratio and circulating bile acids are associated with HPS in patients with advanced liver disease. The study will consist of 400 individuals who are evaluated for liver transplantation at the Field Centers. This population has advanced liver disease and will represent the population with cirrhosis at the Centers. As is considered standard of clinical care for these patients and required for liver transplant evaluation, patients will undergo phlebotomy, interviews, pulmonary function testing, echocardiography, and arterial blood gas sampling at their initial evaluation. During the clinical phlebotomy, additional samples will be drawn for research purposes. If any of these procedures does not occur during the clinical visit, it may be conducted for research purposes. Six minute walk testing, frailty scales, SF36, and optional actigraphy, all of which are research-only assessments, will be performed at baseline. Subjects will then be followed via phone for the duration of the study period.

This study is testing MK-5475 in people with pulmonary hypertension (high blood pressure in the blood vessel of the lung) linked to COPD (a chronic lung disease where it is hard to breathe). You may be able to join Part 2 of this study if you have pulmonary hypertension linked to COPD, and you are at least 40 years old but not more than 80 years old. About 24 subjects will be in Part 2 of this research. People from Part 1 of this study may be allowed to enter Part 2.

The main objective of this study is to analyze sputum collected from the residue remaining from bronchoalveolar lavage (BAL) procedures to compare the cellular characteristics of BAL samples to those of sputum samples collected from the acapella® airway assist device. We intend to enroll volunteers who are being evaluated by an MUSC pulmonologist as part of their standard medical care. The Control Sputum sample will be collected by volunteers at home over a three day period using an acapella® airway assist device. The cellular profiles of the BAL and sputum samples will be analyzed by flow cytometry. Active participation in this study is expected to last less than one month and will be complete once a sample is obtained from the BAL procedure.